TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28431171

Group type: EXPERIMENTAL
Intervention: Monozygotic twins
Number of subjects: 91

Group type: COMPARATOR
Intervention: Dizygotic twins
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 91
Study: 28431485

Group type: EXPERIMENTAL
Intervention: golimumab
Number of subjects: 123
Study: 28431564

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 412
Study: 28431579

Group type: EXPERIMENTAL
Intervention: TSN program implementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison territories (control)
Number of subjects: 0
Study: 28431614

Group type: EXPERIMENTAL
Intervention: Permeability surface area product (PS), cerebral blood flow (CBF), and cerebral blood volume (CBV) calculated within the ischemic territory.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cerebral blood volume (CBV) threshold of 1.7ml/100g.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Complete ischemic region analysis of permeability surface area (PS).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mean PS values for midline shift prediction.
Number of subjects: 200
Study: 28431663

Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28432209

Group type: EXPERIMENTAL
Intervention: Sputum sampling for detection of bacteria and viruses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NTHi airway infection
Number of subjects: 0
Study: 28432444

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS) and Computed tomography (CT)
Number of subjects: 35
Study: 28432612

Group type: EXPERIMENTAL
Intervention: 2 Hz electrical stimulus at the wrist, increasing current intensity from 0-30 mA (5 mA increments), applied for three minutes at each level.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ANI monitoring before and after electrical stimulation.
Number of subjects: 23
Study: 28432691

Group type: EXPERIMENTAL
Intervention: Tenapanor 15 mg twice daily over 4 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cefadroxil 500 mg for 1 day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg and Tenapanor 15 mg on day 5
Number of subjects: 28
Study: 28433206

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 495

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 495
Study: 28433498

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400mg (AOM 400)
Number of subjects: 88
Study: 28433500

Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery (MCCB) administered twice prior to treatment initiation in 1908 patients.
Number of subjects: 2616
Study: 28433924

Group type: EXPERIMENTAL
Intervention: 50-mg deuterium-labeled methyl d9-TMAO (d9-TMAO)
Number of subjects: 40
Study: 28434275

Group type: EXPERIMENTAL
Intervention: Transitional home-based palliative care program
Number of subjects: 84

Group type: COMPARATOR
Intervention: Customary palliative care service
Number of subjects: 84
Study: 28434648

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks (dose-expansion phase)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Nivolumab (dose-escalation phase)
Number of subjects: 262
Study: 28434660

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with reduced-dose radiation (54 Gy for 24 patients with complete or partial responses; 60 Gy for 20 patients with less than partial responses)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (175 mg/m)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with reduced-dose radiation
Number of subjects: 44
Study: 28434702

Group type: EXPERIMENTAL
Intervention: Telmisartan, 10 mg/kg/d in chow
Number of subjects: 0

Group type: COMPARATOR
Intervention: GW9662, 3 mg/kg/d through oral gavage
Number of subjects: 0

Group type: COMPARATOR
Intervention: AT1a KO mice (no treatment mentioned)
Number of subjects: 0
Study: 28434819

Group type: EXPERIMENTAL
Intervention: Functional Test of the Hemiparetic Upper Extremity (FTHUE)
Number of subjects: 109
Study: 28434944

Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV (3×10^6, 1×10^7, and 2×10^7 PFU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV (highest dose cohort)
Number of subjects: 30
Study: 28436937

Group type: EXPERIMENTAL
Intervention: BPS804 (5, 10, and 20 mg/kg) administered intravenously on days 1, 15, and 29
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BPS804
Number of subjects: 8
Study: 28437260

Group type: EXPERIMENTAL
Intervention: Acute post-surgical neuropathic pain assessed using DN4 questionnaire (score ≥ 4/10) on day 0 or day 2.
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Persistent post-surgical neuropathic pain (PPSNP) assessed using DN2 questionnaire (score ≥ 3/7) at 2 months after surgery.
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: DN4 score at least 4/10 on day 0 or day 2 as a risk factor for PPSNP.
Number of subjects: 593
Study: 28437326

Group type: EXPERIMENTAL
Intervention: Intravenous fish oil-based lipid emulsion (FishLE) at a dosage of 1 g·kg·day until resolution of direct hyperbilirubinemia or return of enteral nutrition.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intravenous fish oil-based lipid emulsion (FishLE)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (GA-matched controls)
Number of subjects: 13
Study: 28437380

Group type: EXPERIMENTAL
Intervention: Greater aerobic capacity
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Daily physical activity
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Adherence to the DASH diet
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Greater high-sensitivity C-reactive protein
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Framingham Stroke Risk Profile
Number of subjects: 160
Study: 28437488

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg single oral dose in c.662AG subjects
Number of subjects: 20
Study: 28437668

Group type: EXPERIMENTAL
Intervention: venlafaxine XR
Number of subjects: 98
Study: 28438076

Group type: EXPERIMENTAL
Intervention: Work and Social Engagement (WSAS)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Depressive Symptoms
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: modified Rankin Scale (mRS)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 185
Study: 28438090

Group type: EXPERIMENTAL
Intervention: Composite mesh with polypropylene and expanded polytetrafluoroethylene (Intramesh)
Number of subjects: 90
Study: 28438154

Group type: EXPERIMENTAL
Intervention: Weighted gene co-expression network analysis (WGCNA) applied to peripheral blood transcriptome.
Number of subjects: 238
Study: 28438304

Group type: EXPERIMENTAL
Intervention: Bioresorbable Vascular Scaffold (BVS) implantation
Number of subjects: 1505
Study: 28438723

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical atrial fibrillation ablation (MISAA)
Number of subjects: 109
Study: 28438728

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (twice daily for 6 months) tailored to participant's stage of behavior change
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 31
Study: 28438739

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 13909

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13909
Study: 28439092

Group type: EXPERIMENTAL
Intervention: Ketogenic very-low-energy diet (VLED)
Number of subjects: 31
Study: 28439879

Group type: EXPERIMENTAL
Intervention: PD1 inhibition
Number of subjects: 0
Study: 28440046

Group type: EXPERIMENTAL
Intervention: Paleolithic-type diet (PD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prudent control diet (CD)
Number of subjects: 70
Study: 28440113

Group type: EXPERIMENTAL
Intervention: Endovascular procedures in diabetics
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Endovascular procedures in diabetics with CLI
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Endovascular procedures in diabetics with claudication
Number of subjects: 1906
Study: 28441027

Group type: EXPERIMENTAL
Intervention: β-Blocker Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28441111

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg once every 3 weeks
Number of subjects: 210
Study: 28441695

Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes
Number of subjects: 106
Study: 28442212

Group type: EXPERIMENTAL
Intervention: Underwater ultrasound therapy
Number of subjects: 48
Study: 28442293

Group type: EXPERIMENTAL
Intervention: Appropriate therapy (active drug against the blood isolate started in the first 5 days after infection)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Inappropriate therapy
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Combination therapy (more than one active drug) among those receiving appropriate therapy
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Monotherapy (only one active drug) among those receiving appropriate therapy
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Combination therapy in high-mortality-score stratum
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Monotherapy in high-mortality-score stratum
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Combination therapy in low-mortality-score stratum
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Monotherapy in low-mortality-score stratum
Number of subjects: 437
Study: 28442451

Group type: EXPERIMENTAL
Intervention: Text message survey
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Mobile phone UTI symptom diary app
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Online survey
Number of subjects: 491
Study: 28442453

Group type: EXPERIMENTAL
Intervention: Clickotine app
Number of subjects: 416
Study: 28443046

Group type: EXPERIMENTAL
Intervention: Craving Behavior Intervention (CBI) - six-session intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Craving Behavior Intervention (CBI)
Number of subjects: 63
Study: 28444114

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/day, orally) plus octreotide LAR (30 mg, intramuscularly, every 28 days)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo plus octreotide LAR (30 mg, intramuscularly, every 28 days)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Everolimus plus octreotide LAR
Number of subjects: 429
Study: 28444156

Group type: EXPERIMENTAL
Intervention: Fractional intradermal doses of the inactivated poliovirus vaccine (ID fIPV)
Number of subjects: 0
Study: 28444644

Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 0
Study: 28445112

Group type: EXPERIMENTAL
Intervention: Multiregion whole-exome sequencing on 100 early-stage NSCLC tumors
Number of subjects: 100
Study: 28445469

Group type: EXPERIMENTAL
Intervention: Phylogenetic ctDNA profiling
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative plasma ctDNA analysis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 100
Study: 28445481

Group type: EXPERIMENTAL
Intervention: 5-aza-cytidine (AZA) at 500 nM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZA plus IRI
Number of subjects: 0
Study: 28446129

Group type: EXPERIMENTAL
Intervention: Serum RPR titer ≥1:4
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Serum TPPA titer ≥1:2560
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Parallel testing format of serum RPR titer ≥1:2 and serum TPPA titer ≥1:1280
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Elevated serum creatine kinase
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Serum RPR titer <1:2 and serum TPPA titer <1:1280
Number of subjects: 370
Study: 28446135

Group type: EXPERIMENTAL
Intervention: ROM Plus®
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: AmniSure®
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: ROM Plus® (term patients ≥37 weeks)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: AmniSure® (term patients ≥37 weeks)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both tests (preterm patients <37 weeks)
Number of subjects: 111
Study: 28446181

Group type: EXPERIMENTAL
Intervention: NMES-robot hybrid system
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NMES applied to agonist muscles
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Device assisted upper limb training
Number of subjects: 11
Study: 28446192

Group type: EXPERIMENTAL
Intervention: Trinity Evolution® (TE) viable cellular bone allograft
Number of subjects: 40
Study: 28446244

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Further antiepileptic drugs (AED)
Number of subjects: 0
Study: 28446419

Group type: EXPERIMENTAL
Intervention: SPPAC program (14 sessions, ~30 min each over 10 weeks) delivered by a peer trainer using a mobile phone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Existing PA guidelines
Number of subjects: 38
Study: 28446421

Group type: EXPERIMENTAL
Intervention: Speed of processing training, a computerized Internet cognitive training program.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 28446495

Group type: EXPERIMENTAL
Intervention: High-volume energy drink (946 mL, 320 mg caffeine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Caffeinated control drink (320 mg caffeine)
Number of subjects: 18
Study: 28446498

Group type: EXPERIMENTAL
Intervention: Diet quality assessment
Number of subjects: 0
Study: 28446501

Group type: EXPERIMENTAL
Intervention: Dietary long-chain fatty acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28446521

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 46
Study: 28446560

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28447475

Group type: EXPERIMENTAL
Intervention: Olaratumab plus doxorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 0
Study: 28448562

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADL)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Etanercept (ETN)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADL) and Infliximab (IFX)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: All treatments (ETN, ADL, IFX)
Number of subjects: 595
Study: 28448594

Group type: EXPERIMENTAL
Intervention: HIVconsv vaccines
Number of subjects: 12
Study: 28448662

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) followed by surgical resection in arm B (n=60)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy with FLOT in arm C (n=127)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with FLOT followed by surgery in arm B (n=36 who proceeded to surgery)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Patients in arm B (n=60)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Patients in arm C (n=127)
Number of subjects: 252
Study: 28449055

Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFOX (PRIME)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFOX (PEAK)
Number of subjects: 675

Group type: COMPARATOR
Intervention: FOLFOX alone (PRIME)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFOX (PEAK)
Number of subjects: 675
Study: 28449090

Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption (mean BAC 0.85 g/kg)
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Chronic alcohol consumption (KORA S4 Study)
Number of subjects: 3028
Study: 28449352

Group type: EXPERIMENTAL
Intervention: Ziconotide as the first agent in pump (FIP+)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Not first intrathecal agent in pump (FIP-)
Number of subjects: 93
Study: 28449642

Group type: EXPERIMENTAL
Intervention: Double incision technique
Number of subjects: 22

Group type: COMPARATOR
Intervention: Single incision technique
Number of subjects: 22
Study: 28449658

Group type: EXPERIMENTAL
Intervention: Movie Models online video intervention for parents, delivered over 4 weeks.
Number of subjects: 0
Study: 28449674

Group type: EXPERIMENTAL
Intervention: Exclusive chemotherapy
Number of subjects: 0
Study: 28449675

Group type: EXPERIMENTAL
Intervention: Fever Assessment Tool (FAST)
Number of subjects: 68
Study: 28449772

Group type: EXPERIMENTAL
Intervention: WiSE-CRT system (wireless left ventricular endocardial pacing)
Number of subjects: 35
Study: 28449783

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 28449809

Group type: EXPERIMENTAL
Intervention: Crizotinib (part of the AcSé phase 2 trial, NCT02034981)
Number of subjects: 1
Study: 28450272

Group type: EXPERIMENTAL
Intervention: TAVIE en m@rche intervention (4-week intervention plus a brief booster at 8 weeks)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group receiving hyperlinks to publicly available websites
Number of subjects: 148
Study: 28450351

Group type: EXPERIMENTAL
Intervention: Adenosine (25 μg/kg; 1.5 mg if ≥60 kg)
Number of subjects: 80
Study: 28450544

Group type: EXPERIMENTAL
Intervention: VWFA
Number of subjects: 33
Study: 28450567

Group type: EXPERIMENTAL
Intervention: Circulating tumor cells (CTCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma cell-free DNA (cfDNA)
Number of subjects: 0
Study: 28450894

Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a 125 mcg every 2 weeks
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1512
Study: 28451922

Group type: EXPERIMENTAL
Intervention: Mentor Mothers (MM) conducting home visits
Number of subjects: 101
Study: 28453532

Group type: EXPERIMENTAL
Intervention: Cogmed QM computerized working memory training (25 sessions, 5 days/week for 5 weeks)
Number of subjects: 9
Study: 28453629

Group type: EXPERIMENTAL
Intervention: Rapid deployment aortic valve replacement with Edwards INTUITY valve system
Number of subjects: 295
Study: 28453692

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg intravenously every 2 weeks for up to 2 years or until progression or unacceptable toxicity
Number of subjects: 43
Study: 28453697

Group type: COMPARATOR
Intervention: TNM staging alone
Number of subjects: 3016

Group type: EXPERIMENTAL
Intervention: Models with added molecular markers (MSI, BRAFV600E, KRAS)
Number of subjects: 3016

Group type: EXPERIMENTAL
Intervention: Models with clinicopathological features
Number of subjects: 3016

Group type: EXPERIMENTAL
Intervention: Models with all covariates (TNM, molecular markers, clinicopathological features)
Number of subjects: 3016

Group type: COMPARATOR
Intervention: TNM alone model
Number of subjects: 3016

Group type: EXPERIMENTAL
Intervention: Models including clinicopathological features
Number of subjects: 3016

Group type: EXPERIMENTAL
Intervention: TNM, clinicopathological features, and molecular markers
Number of subjects: 3016
Study: 28453704

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and trastuzumab
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HER2-enriched subtype (RNA-seq analysis)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-level or no ERBB2 amplification
Number of subjects: 48
Study: 28453702

Group type: EXPERIMENTAL
Intervention: Motolimod combined with pegylated liposomal doxorubicin (PLD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo combined with pegylated liposomal doxorubicin (PLD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motolimod (in subset analysis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment in vitro responses of immune biomarkers to TLR8 stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune score (tumor infiltrating lymphocytes; TIL), TLR8 single-nucleotide polymorphisms, mutational status in BRCA and other DNA repair genes, and autoantibody biomarkers
Number of subjects: 0
Study: 28453773

Group type: EXPERIMENTAL
Intervention: CSF GABA in women with PCOS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CSF testosterone in women with PCOS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CSF estradiol in women with PCOS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Circulating testosterone in women with PCOS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Circulating estradiol in women with PCOS
Number of subjects: 27

Group type: COMPARATOR
Intervention: CSF glucose and glutamate concentrations
Number of subjects: 27
Study: 28454122

Group type: EXPERIMENTAL
Intervention: Olaparib plus irinotecan (IC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Olaparib plus irinotecan and mitomycin C (ICM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study: 28454530

Group type: EXPERIMENTAL
Intervention: Population-based cohort
Number of subjects: 2141

Group type: COMPARATOR
Intervention: Cohort with overweight/obesity
Number of subjects: 2141
Study: 28454531

Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention program (225 min/week increase in physical activity, in addition to 90 min/week of ordinary PA)
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention program
Number of subjects: 1545
Study: 28454793

Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Left transradial access (left TRA)
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Right transradial access (right TRA)
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Use of adjunctive protective pelvic drapes
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Left projections and use of angiographic systems not dedicated for coronary and high frame rates
Number of subjects: 2028
Study: 28454922

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334